A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs Finerenone (Primary)
- Indications Proteinuria; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms FIONA
- Sponsors Bayer
- 08 Nov 2024 Planned End Date changed from 11 Mar 2027 to 31 Aug 2027.
- 08 Nov 2024 Planned primary completion date changed from 11 Feb 2027 to 31 Jul 2027.
- 12 Mar 2024 According to the trial design published in the Trials, A sample size of 198 participants (aged 2 to <18 years) in FIONA will provide at least 80% power to reject the null hypothesis of either of the two primary endpoints.